Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase

被引：10
|
作者：
Bradshaw, D.
Malik, S.
Booth, C.
Van Houtte, M.
Pattery, T.
Waters, A.
Ainsworth, J.
Geretti, A. M.
机构：
[1] Royal Free Hosp, Dept Virol, London NW3 2QG, England
[2] UCL, Sch Med, Royal Free Hosp, London W1N 8AA, England
[3] Virco BVBA, Mechelen, Belgium
[4] N Middlesex Hosp, Dept HIV Med, London, England
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 12期
关键词：
D O I：
10.1128/AAC.00687-07
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.
引用
收藏
页码：4489 / 4491
页数：3
相关论文
共 50 条
  • [1] Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Turner, D
    Brenner, B
    Wainberg, MA
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (06) : 979 - 981
  • [2] Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase
    Diallo, K
    Götte, M
    Wainberg, MA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3377 - 3383
  • [3] Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients
    Turner, D
    Brenner, BG
    Routy, JP
    Petrella, M
    Wainberg, MA
    MICROBIOLOGICA, 2004, 27 (02): : 31 - 39
  • [4] Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Diallo, K
    Oliveira, M
    Moisi, D
    Brenner, B
    Wainberg, MA
    Götte, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) : 2254 - 2256
  • [5] The influence of 3TC-resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency
    Hamburgh, ME
    Drosopoulos, WC
    Prasad, VR
    NUCLEIC ACIDS RESEARCH, 1998, 26 (19) : 4389 - 4394
  • [6] New Perspectives on the Virologic Consequences of M184V or I in Human Immunodeficiency Virus-1 Reverse Transcriptase
    Kuritzkes, Daniel R.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (07): : 1067 - 1069
  • [7] Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in rhesus monkeys
    Newstein, MC
    Desrosiers, RC
    JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (10): : 1262 - 1267
  • [8] Apricitabine Does Not Select Additional Drug Resistance Mutations in Tissue Culture in Human Immunodeficiency Virus Type 1 Variants Containing K65R, M184V, or M184V plus Thymidine Analogue Mutations
    Oliveira, Maureen
    Moisi, Daniela
    Spira, Bonnie
    Cox, Susan
    Brenner, Bluma G.
    Wainberg, Mark A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (04) : 1683 - 1685
  • [9] Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations
    Frankel, Fernando A.
    Invernizzi, Cedric F.
    Oliveira, Maureen
    Wainberg, Mark A.
    AIDS, 2007, 21 (06) : 665 - 675
  • [10] Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase
    Van Rompay, KKA
    Matthews, TB
    Higgins, J
    Canfield, DR
    Tarara, RP
    Wainberg, MA
    Schinazi, RF
    Pedersen, NC
    North, TW
    JOURNAL OF VIROLOGY, 2002, 76 (12) : 6083 - 6092
12345